NCT05681715 2025-11-06A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)UCB PharmaPhase 3 Completed62 enrolled 11 charts
NCT04650854 2025-04-18A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisUCB PharmaPhase 3 Completed165 enrolled 21 charts